Advertisement
Advertisement
VTVT
vTv Therapeutics Inc. Class A Common Stock
30.68
USDSponsored
-0.36
-1.16%
May 08, 15:58 UTC -4
Closed
After-Market
30.82
+0.14
+0.47%
VTVT Earnings Reports
Positive Surprise Ratio
VTVT beat 22 of 35 last estimates.
63%
Next Report
In 3 Days
Date of Next Report
May 13, 2026
Estimate for Q1 26 (Revenue/ EPS)
$20.40M
/-$0.09
Implied change from Q4 25 (Revenue/ EPS)
--
/-84.21%
Implied change from Q1 25 (Revenue/ EPS)
--
/-88.31%
vTv Therapeutics Inc. Class A Common Stock earnings per share and revenue
On Mar 10, 2026, VTVT reported earnings of -0.57 USD per share (EPS) for Q4 25, beating the estimate of -1.10 USD, resulting in a 47.74% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +0.23% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 4 analysts forecast an EPS of -0.09 USD, with revenue projected to reach 20.40 million USD, implying an decrease of -84.21% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
Entera Bio Ltd. Ordinary Shares
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.07
Surprise
+54.25%
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
FAQ
What were vTv Therapeutics Inc. Class A Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, vTv Therapeutics Inc. Class A Common Stock reported EPS of -$0.57, beating estimates by 47.74%, and revenue of $0.00, 0% as expectations.
How did the market react to vTv Therapeutics Inc. Class A Common Stock's Q4 2025 earnings?
The stock price moved up 0.23%, changed from $35.02 before the earnings release to $35.10 the day after.
When is vTv Therapeutics Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for May 13, 2026.
What are the forecasts for vTv Therapeutics Inc. Class A Common Stock's next earnings report?
Based on 4
analysts, vTv Therapeutics Inc. Class A Common Stock is expected to report EPS of -$0.09 and revenue of $20.40M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement